Effects of Orally Administered Cannabidiol on Neuroinflammation and Intestinal Inflammation in the Attenuation of Experimental Autoimmune Encephalomyelitis

Dopkins, Nicholas; Miranda, Kathryn; Wilson, Kiesha; Holloman, Bryan Latrell; Nagarkatti, Prakash; Nagarkatti, Mitzi

doi:10.1007/s11481-021-10023-6

Cited by 29 publications

(28 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cannabinoids have also been shown to promote a reparative activation state of microglia and macrophages, diminishing the reactivity and the number of microglia in Theiler's virus-induced demyelination disease [128]. RNA sequencing analysis has revealed that oral CBD treatment of EAE mice can reduce the expression of CXCL9, CXCL10, and IL-1β, leading to decreased macrophage infiltration into the CNS, and also induce myeloid-derived suppressor cells (MDSCs) [191].…”

Section: Mechanisms That Would Inhibit Innate Immune Assaults On Cns ...mentioning

confidence: 99%

“…The inhibition of autoreactive T-cell proliferation following treatment with cannabinoids is believed to be the result of the increased mobilization, recruitment, and enhanced potency of MDSCs in response to cannabinoid receptor activation, leading to increased apoptotic cell death of CD4+ T cells in the brain [85,191,193]. Other mechanisms that may contribute to cannabinoid inhibition of T-cell responses are their ability to induce IL-10 and TGF-β, inhibit IL-2, and Th17/Th1 differentiation, influence the mechanism of antigen presentation, and impede adhesion by downregulation of migration-related signaling pathways [106,123,194].…”

Section: Mechanisms That Would Downregulate Antigen-specific Adaptive...mentioning

confidence: 99%

See 1 more Smart Citation

Neurological Benefits, Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: A Systematic Review of Cannabinoid Effects in Multiple Sclerosis and Experimental Models of Demyelination

et al. 2022

View full text Add to dashboard Cite

Despite current therapeutic strategies for immunomodulation and relief of symptoms in multiple sclerosis (MS), remyelination falls short due to dynamic neuropathologic deterioration and relapses, leading to accrual of disability and associated patient dissatisfaction. The potential of cannabinoids includes add-on immunosuppressive, analgesic, neuroprotective, and remyelinative effects. This study evaluates the efficacy of medical marijuana in MS and its experimental animal models. A systematic review was conducted by a literature search through PubMed, ProQuest, and EBSCO electronic databases for studies reported since 2007 on the use of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) in MS and in experimental autoimmune encephalomyelitis (EAE), Theiler’s murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD), and toxin-induced demyelination models. Study selection and data extraction were performed by 3 reviewers, and 28 studies were selected for inclusion. The certainty of evidence was appraised using the Cochrane GRADE approach. In clinical studies, there was low- and moderate-quality evidence that treatment with ~1:1 CBD/THC mixtures as a nabiximols (Sativex®) oromucosal spray reduced numerical rating scale (NRS) scores for spasticity, pain, and sleep disturbance, diminished bladder overactivity, and decreased proinflammatory cytokine and transcription factor expression levels. Preclinical studies demonstrated decreases in disease severity, hindlimb stiffness, motor function, neuroinflammation, and demyelination. Other experimental systems showed the capacity of cannabinoids to promote remyelination in vitro and by electron microscopy. Modest short-term benefits were realized in MS responders to adjunctive therapy with CBD/THC mixtures. Future studies are recommended to investigate the cellular and molecular mechanisms of cannabinoid effects on MS lesions and to evaluate whether medical marijuana can accelerate remyelination and retard the accrual of disability over the long term.

show abstract

Section: Mechanisms That Would Inhibit Innate Immune Assaults On Cns ...mentioning

confidence: 99%

Section: Mechanisms That Would Downregulate Antigen-specific Adaptive...mentioning

confidence: 99%

Neurological Benefits, Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: A Systematic Review of Cannabinoid Effects in Multiple Sclerosis and Experimental Models of Demyelination

et al. 2022

View full text Add to dashboard Cite

show abstract

“…These two phyto-cannabinoids utilize different endocannabinoid receptors to mediate their effects. A few studies have demonstrated anti-inflammatory effect for phytocannabinoid treatments on macrophage function, however, these studies have generally focused on a single cannabinoid [ 25 , 26 , 27 , 28 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

Differential Effects of D9 Tetrahydrocannabinol (THC)- and Cannabidiol (CBD)-Based Cannabinoid Treatments on Macrophage Immune Function In Vitro and on Gastrointestinal Inflammation in a Murine Model

et al. 2022

View full text Add to dashboard Cite

Phytocannabinoids possess a wide range of immune regulatory properties, mediated by the endocannabinoid system. Monocyte/macrophage innate immune cells express endocannabinoid receptors. Dysregulation of macrophage function is involved in the pathogenesis of different inflammatory diseases, including inflammatory bowel disease. In our research, we aimed to evaluate the effects of the phytocannabinoids D9 tetrahydrocannabinol (THC) and cannabidiol (CBD) on macrophage activation. Macrophages from young and aged C57BL/6 mice were activated in vitro in the presence of pure cannabinoids or cannabis extracts. The phenotype of the cells, nitric oxide (NO•) secretion, and cytokine secretion were examined. In addition, these treatments were administered to murine colitis model. The clinical statuses of mice, levels of colon infiltrating macrophages, and inflammatory cytokines in the blood, were evaluated. We demonstrated inhibition of macrophage NO• and cytokine secretion and significant effects on expression of cell surface molecules. In the murine model, clinical scores were improved and macrophage colon infiltration reduced following treatment. We identified higher activity of cannabis extracts as compared with pure cannabinoids. Each treatment had a unique effect on cytokine composition. Overall, our results establish that the effects of cannabinoid treatments differ. A better understanding of the reciprocal relationship between cannabinoids and immunity is essential to design targeted treatment strategies.

show abstract

“…Possible benefits have been raised with cannabinoid derivatives in the management of neuropathic pain [ 34 ] and neuroinflammation [ 35 ]. The effects of cannabinoids and their interaction in the body are yet to be fully understood; however, the therapeutic effects of some cannabinoid derivatives are already approved for in the management of chronic pain and co-occurring conditions in some countries.…”

Section: Introductionmentioning

confidence: 99%

“…In the immune system, endocannabinoid signaling modulates the immune and inflammatory response in multiple states [ 38 ]. Preclinical studies demonstrate the beneficial effect of CBD treatment on autoimmune neuroinflammation by suppressing the expression of proinflammatory chemoattractants and regulating the activity of inflammatory macrophages [ 35 ]. Recent evidence shows that medical cannabis or cannabinoids result in little to very little improvement in pain relief, physical functioning, and quality of sleep among chronic pain patients [ 39 ].…”

Section: Introductionmentioning

confidence: 99%

A Systematic Review on Cannabinoids for Neuropathic Pain Administered by Routes Other than Oral or Inhalation

Quintero

Pulido

Giraldo

et al. 2022

Plants

View full text Add to dashboard Cite

The use of cannabis and cannabinoid products for the treatment of neuropathic pain is a growing area of research. This type of pain has a high prevalence, limited response to available therapies and high social and economic costs. Systemic cannabinoid-based therapies have shown some unwanted side effects. Alternative routes of administration in the treatment of neuropathic pain may provide better acceptance for the treatment of multiple pathologies associated with neuropathic pain. To examine the efficacy, tolerability, and safety of cannabinoids (individualized formulations, phytocannabinoids, and synthetics) administered by routes other than oral or inhalation compared to placebo and/or conventional medications in the management of neuropathic pain. This systematic review of the literature reveals a lack of clinical research investigating cannabis by routes other than oral and inhalation as a potential treatment for neuropathic pain and highlights the need for further investigation with well-designed clinical trials. There is a significant lack of evidence indicating that cannabinoids administered by routes other than oral or inhaled may be an effective alternative, with better tolerance and safety in the treatment of neuropathic pain. Higher quality, long-term, randomized controlled trials are needed to examine whether cannabinoids administered by routes other than inhalation and oral routes may have a role in the treatment of neuropathic pain.

show abstract

Effects of Orally Administered Cannabidiol on Neuroinflammation and Intestinal Inflammation in the Attenuation of Experimental Autoimmune Encephalomyelitis

Cited by 29 publications

References 75 publications

Neurological Benefits, Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: A Systematic Review of Cannabinoid Effects in Multiple Sclerosis and Experimental Models of Demyelination

Neurological Benefits, Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: A Systematic Review of Cannabinoid Effects in Multiple Sclerosis and Experimental Models of Demyelination

Differential Effects of D9 Tetrahydrocannabinol (THC)- and Cannabidiol (CBD)-Based Cannabinoid Treatments on Macrophage Immune Function In Vitro and on Gastrointestinal Inflammation in a Murine Model

A Systematic Review on Cannabinoids for Neuropathic Pain Administered by Routes Other than Oral or Inhalation

Contact Info

Product

Resources

About